Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Nephropathy Type 2 Clear all
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Losartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Diabetic Nephropathy, Chronic Kidney Disease
Interventions
Zemplar (paricalcitol) capsules, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
27
States / cities
Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Kidney Disease
Interventions
canagliflozin, Aminohippurate Sodium Inj 20%
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Lisinopril, Nifedipine, Simvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Disease
Interventions
AZD9977, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 130 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced May 22, 2026, 4:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ACEI or ARB, Lisinopril
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced May 22, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
Interventions
Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Glendale, California • Los Angeles, California • San Dimas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases
Interventions
GFB-024, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Type2diabetes, Diabetic Kidney Disease
Interventions
Investigational Product - MIB 626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 4:14 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Focus Type 2 Diabetes Related Chronic Kidney Disease
Interventions
Exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Birmingham, Alabama • Chula Vista, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
ALN-ANG3, Evinacumab, ALN-ANG3 placebo, Evinacumab placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
51
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 4:14 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions
Pegloticase 8 MG/ML [Krystexxa]
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
Interventions
Cholecalciferol, Placebo
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Bardoxolone methyl (amorphous dispersion)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Boise, Idaho • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Sulodexide, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Calcitriol, Losartan
Dietary Supplement · Drug
Lead sponsor
Weill Cornell Medical College in Qatar
Other
Eligibility
21 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced May 22, 2026, 4:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 4:14 AM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced May 22, 2026, 4:14 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
Kidney-Protective Therapies Used in Routine Care
Drug
Lead sponsor
Rubix LS
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced May 22, 2026, 4:14 AM EDT